Cardiac Markers Fluorescent Immunoassay

Dec. 26, 2017

Creative Diagnostics^® offers a series of fluorescent immunoassay test strips for quantitatively detecting cardiac markers in human serum, whole blood or plasma specimens. The detection sensitivity is up to pg/ml level.

Cardiac Marker Fluorescent Test Strips

---

•  Rapid, convenient and simple operation

•  Accurate quantification

•  Fluorescence signaling, higher sensitivity and specificity

•  Room temperature storage, tests can be run immediately as needed

Cat. No.	Product Name	Sensitivity	Linear range
DTSJYJ062	CDIATM Troponin I Immunofluorescence Test Cassette, Serum/Whole Blood/Plasma	0.16 ng/mL	0.16-32 ng/mL
DTSJYJ063	CDIATM Creatine Kinase MB Immunofluorescence Test Cassette, Serum/Whole Blood/Plasma	0.32 ng/mL	0.32-80 ng/mL
DTSJYJ064	CDIATM D-Dimer Immunofluorescence Test Cassette, Whole Blood/Plasma	0.1 mg/L	0.1-10 mg/L
DTSJYJ065	CDIATM Myoglobin Immunofluorescence Test Cassette, Serum/Whole Blood/Plasma	2.4 ng/mL	2.4-400 ng/mL
DTSJYJ066	CDIATM NT-proBNP Immunofluorescence Test Cassette, Serum/Whole Blood/Plasma	18 pg/mL	50-25000 pg/mL
DTSJYJ067	CDIATM Fatty Acid-binding Protein Immunofluorescence Test Cassette, Serum/Whole Blood/Plasma	1 ng/mL	1-100 ng/mL
DTSJYJ068	CDIATM C-reactive Protein Immunofluorescence Test Cassette, Serum/Whole Blood/Plasma	0.5 ng/mL	0.5-100 ng/mL

The immunofluorescent signal of cardiac marker fluorescent test strip is measured by Creative Diagnostics Fluorescent Immunoassay Analyzer FIA7100 to deliver accurate, objective and automated results.

Cat. No.	Product Name	Signal detection
DTSJYJ062	FIA7100 Fluorescent immunoassay analyzer	Time resolved fluorescence (TRF)

Cardiac markers

---

Cardiac markers are used in the diagnosis and risk stratification of patients with chest pain and suspected acute coronary syndrome (ACS). Measuring cardiac biomarkers can be a step toward making a diagnosis for a condition. Cardiac markers help physicians to assess acute coronary syndromes and to identify and manage high-risk patients. Presently, there exist POC immunoassays for several cardiac markers including creatine kinase MB (CK-MB), myoglobin, troponin I, and troponin T that yield qualitative and quantitative results comparable to traditional central lab assays. Existing POC assays combining myoglobin and CK-MB have high sensitivity and specificity for diagnosing acute myocardial infarction and may provide the earliest identification of myocardial injury. POC Troponin T assays are the most studied POC cardiac marker assays. Along with POC troponin I assays, these tests provide more sensitive identification of myocardial injury and valuable prognostic information.

The table below shows certain biomarkers that are used to help diagnose, evaluate, and monitor people suspected of having Acute Coronary Syndrome (ACS).

Biomarker	Structure	Tissue Source	Function in disease
CK-MB	Heart-related isoenzymes of CK	Heart, brain, and skeletal muscle	Increasing levels indicate injury to heart and can remain elevated for up to 7 to 14 days after attack. This enables physicians to be able to diagnose heart attack and assist in management of treatment.
Myoglobin	Oxygen-storing protein	Heart and other muscle cells	Increased levels are indicative to injury to skeletal muscle or heart cells. I sometimes performed with Troponin to provide early diagnosis of heart attack.
Cardiac Troponin	Consists of 2 cardiac specific isoforms: T and I	Heart	Increasing levels indicate injury to heart and can remain elevated for up to 7 to 14 days after attack. This enables physicians to be able to diagnose heart attack and assist in management of treatment.

CDIA^TM cardiac marker fluorescent test is designed using antibody sandwich assay for the detection of cardiac markers. The fluorescence immunoassay offers potential advantages of sensitivity, simplicity and reproducibility. In a comparison with colloidal gold-based test, the detection limit of the test was 100 or more times lower. Improvements in photonic crystal performance can be made to further lower the detection limit that is useful in detecting biomarkers associated with the disease. Significantly reduces the time to treatment of heart patients The more quickly you identify high-risk ACS, the sooner therapy can begin, saving time, money, heart muscle and precious human lives.